Who Owns Intellia Therapeutics Stock?
NASDAQ: NTLAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 99.95%
- Institutions (% of float)
- 103.94%
- Held by insiders
- 3.84%
- Institutional holders
- 433
- Institutions 96.2%
- Insiders 3.8%
- Public and other 0.0%
Who owns Intellia Therapeutics stock?
Institutional investors own about 100.0% of Intellia Therapeutics's shares, spread across 433 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 3.84% of NTLA.
The largest institutional holders are ARK Investment Management, LLC (12.04%), Blackrock Inc. (11.00%) and State Street Corporation (6.59%). Together, the top 10 institutions control 56.8% of shares outstanding. In their latest filings, 9 of the top 10 institutions increased their NTLA positions and 0 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of NTLA
| Institution | Shares | % Held | Change |
|---|---|---|---|
| ARK Investment Management, LLC | 16.88M | 12.04% | +16.3% |
| Blackrock Inc. | 15.41M | 11.00% | +26.8% |
| State Street Corporation | 9.23M | 6.59% | +33.4% |
| Vanguard Portfolio Management LLC | 7.33M | 5.23% | +17.8% |
| Shaw D.E. & Co., Inc. | 6.44M | 4.60% | +12.5% |
| Vanguard Capital Management LLC | 6.03M | 4.30% | +18.6% |
| Two Sigma Investments, LP | 5.24M | 3.74% | +11.3% |
| FMR, LLC | 4.77M | 3.41% | +130.9% |
| RA Capital Management, L.P. | 4.53M | 3.23% | +100.0% |
| Regeneron Pharmaceuticals Inc | 3.70M | 2.64% | 0.0% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of NTLA
| Fund | Shares | % Held |
|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 9.61M | 6.86% |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 6.06M | 4.33% |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.29M | 3.06% |
| iShares Trust-iShares Russell 2000 ETF | 3.47M | 2.48% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3.11M | 2.22% |
| ARK ETF Trust-ARK Genomic Revolution ETF | 2.72M | 1.94% |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.91M | 1.37% |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.80M | 1.28% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.60M | 1.15% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.48M | 1.06% |
Frequently asked questions
Who is the largest shareholder of Intellia Therapeutics?
ARK Investment Management, LLC is the largest institutional shareholder of NTLA, owning 12.04% of shares outstanding (16.88M shares) as of its latest 13F filing.
What percentage of Intellia Therapeutics is owned by institutions?
Institutions own about 100.0% of NTLA shares and 103.9% of the public float.
How much of Intellia Therapeutics do insiders own?
Insiders, such as officers and directors, own about 3.84% of NTLA shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.